Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy combinations and the promise of several novel immunotherapies, including anti-IDO1 checkpoint blockade and a personalized, patient-specific vaccine. Other measures of immunotherapy’s effectiveness, such as patient quality of life, were also discussed. Below are some of the most important findings that were revealed today:
Multiple Tumor Types:
Head and Neck Cancer:
Melanoma / Skin Cancers:
Stomach & Gastrointestinal Cancer:
ASCO17: Day 2 Immunotherapy Highlights
Read Previous Article
ASCO17: Days 4 and 5 Immunotherapy Highlights
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Behind-the-scenes of a new based-on-a-true-story comedy web series, “Homesick,” about an American living in London with a woman battling cancer and her nine-year-old daughter.
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only chemotherapy and radiation